Combinations of nucleoside/nucleotide analogues for HIV therapy

AIDS Reviews

Volumn 6, Issue 4, 2004, Pages 234-243

  Barreiro, Pablo ^a   García Benayas, Teresa ^a   Rendón, Ana ^a   Rodríguez Novoa, Sonia ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Nucleoside analogues; Nucleotides; Pharmacokinetics; Purine nucleoside phosphorylase

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; AMPRENAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NUCLEOSIDE ANALOG; RITONAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

AREA UNDER THE CURVE; BONE MARROW DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DESIGN; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG METABOLISM; HEMATOLOGIC DISEASE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LIPOATROPHY; MEDICAL DECISION MAKING; META ANALYSIS; PANCREATITIS; PERIPHERAL NEUROPATHY; REVIEW; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

ADENINE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIDEOXYNUCLEOSIDES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; PHOSPHONIC ACIDS;

EID: 13644262826     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Dudley M. Clinical pharmacokinetics of nucleoside antiretroviral agents. J Infect Dis 1995;171 Suppl 2:99-112.
2. Stretcher B, Pesce A, Frame P, et al. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV. Antimicrob Agents Chemother 1994; 1541-7.
3. Rodríguez J, Rodriguez J, Santana J, et al. Simultaneous quantitation of intracellular zidovudine and lamivudine triphosphates in HIV-infected individuals. Antimicrob Agents Chemother 2000;44:3097-100.
4. Ruane P, Richmon G, DeJesus E, et al. Pharmacodynamic effects of zidovudine 600 mg once/day vs. 300 mg twice/day in therapy-naive patients infected with HIV. Pharmacotherapy 2004;24:307-12.
5. Beach J. Chemotherapeutic agents for HIV infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions. Clin Ther 1998;20:2-25.
6. Stein D, Moore K. Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians. Pharmacotherapy 2001;21;11-34.
7. Yuen G, Lou Y, Bumgarner N, et al. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 mg once daily and 150 mg twice daily. Antimicrob Agents Chemother 2004;48:176-82.
8. Moore K, Barrett J, Shaw S, et al. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1, AIDS 1999;13:2239-50.
9. Bruno R, Regazzi M, Ciappina V, et al. Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIV. Clin Pharmacokinet 2001;40:695-700.
10. Hazen R, Lanier E. Relative anti-HIV-1 efficacy of lamivudine and emtricitabine in vitro is dependent on cell type. J Acquir Immune Defic Syndr 2003;32:255-8.
11. Bang L, Scoff L. Emtricitabine: an antiretroviral agent for HIV infection. Drugs 2003;63:2413-24.
12. Foster R, Faulds D. Abacavir. Drugs 1998;55:729-38.
13. Faletto M, Miller W, Garvey E, et al. Unique intracellular activation of the potent anti-HIV agent 1592U89. Antimicrob Agents Chemother 1997;41:1099-107.
14. Pilero P, Shachoy-Clark A, Para M, et al. A study examining the pharmacokinetics of abacavir and the intracellular carbovir triphosphate. 43rd ICAAC; 2003; Chicago (IL) [abstract A-1615].
15. Harris M, Back D, Kewn S, et al. Intracellular carbovir triphosphate levels in patients taking abacavir once a day. AIDS 2002;16:1196-7.
16. Drusano G, Bilello P, Symonds W, et al. Pharmacodynamics of abacavir in an in vitro hollow-fiber model system. Antimicrob Agents Chemother 2002;46:464-70.
17. Gazzard B, DeJesus E, Cahn P, et al. Abacavir qd plus lamivudine qd in combination with efavirenz qd is well tolerated and effective in the treatment of antiretroviral therapy naive adults with HI-1 infection (ZODIAC study: CNA30021). 43rd ICAAC; 2003; Chicago (IL) [abstract H-1722b].
18. Barreiro P, Corbatón A, Núñez M, González-Lahoz J, Soriano V. Tolerability of didanosine as enteric-coated capsules vs. buffered tablets. AIDS Pat Care 2004;18:329-31.
19. Pollard R. Didanosine once daily: potential for expanded use. AIDS 2000;14:2421-8.
20. Hoetelmans R, Van Heeswijk R, Profijt R, et al. Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals. AIDS 1998;12:211-6.
21. Maggiolo F, Ripamonti D, Gregis G, et al. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients. Antivir Ther 2003;8:339-46.
22. Barditch-Crovo P, Deeks S, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in HIV-infected adults. Antimicrob Agents Chemother 2001;45:2733-9.
23. Gathe J, Podzamczer D, Johnson M, et al. Once daily vs. twice daily lopinavir/ritonavir in antiretroviral-naive patients: 48-week results. 11th CROI; 2004; San Francisco (CA) [abstract 570].
24. Pozniak A, Gallant J, Staszewski S, et al. Long-term efficacy and safety of TDF: a 144-week comparison vs. d4T in antiretroviral-naive patients. 7th Intl Congress on Drug Therapy in HIV Infection; 2004; Glasgow [abstract p2].
25. Robbins G, De Gruttola V, Shafer R, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003;349:2293-303.
26. Shafer R, Smeaton L, Robbins G, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003;349:2304-15.
27. Arribas J, DeJesus E, Campo R, et al. The combination of tenofovir DF, emtricitabine and efavirenz has significantly greater response vs. fixed dose zidovudine/lamivudine and efavirenz in antiretroviral naive patients. 7th Intl Congress on Drug Therapy in HIV Infection; 2004; Glasgow [abstract PL14.2].
28. Larder B, Kemp S, Harrigan P. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995;269:696-9.
29. Melby T, Tortell S, Thorborn D, et al. Time to appearance of NRTI-associated mutations and response to subsequent therapy for patients failing on ABC/COM. 8th CROI; 2001; Chicago (IL) [abstract 448].
30. Squires K, Gulick R, Tebas P, et al. A comparison of stavudine plus lamivudine vs. zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection. AIDS 2000;14:1591-600.
31. Panel on Clinical Practices for the Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. October 29, 2004. Available at http://www.aidsinfo.nih.gov
32. Bartlett J, Johnson J, Herrera G, et al. Abacavir/lamivudine in combination with efavirenz, amprenavir/ritonavir or stavudine: ESS40001 (CLASS) preliminary 48 weeks results. 14th Intl AIDS Conference; 2002; Barcelona [abstract TuOrB1189].
33. DeJesus E, Herrera G, Teofilo E, et al. Efficacy and safety of ABC vs. ZDV in antiretroviral therapy naive adults with HIV-1 infection (study CNA 30024). 43rd ICAAC; 2003; Chicago (IL) [abstract H-446]
34. Staszewski S, Haberl A, Carlebach A, et al. A simple, once daily dosing regimen for treating HIV-1 infection in intravenous drug users. HIV Medicine 2000;1:162-3.
35. Maggiolo F, Migliorino M, Maserati R, et al. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antiviral Therapy 2002;6:249-53.
36. Hsieh S, Hung C, Lu P, et al. Preliminary experience of adverse drug reactions, tolerability, and efficacy of a once daily regimen of antiretroviral combination therapy. J Acquir Immune Defic Syndr 2000;24:287.
37. De Mendoza C, Soriano V, Perez-Olmeda M, et al. Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in HIV-infected patients. J Hum Virol 2000;3:335-40.
38. Saag M, Cahn P, Raffi F, et al. Efficacy and safety of emtricitabine vs. stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA 2004;292:180-9.
39. Wainberg M, Miller M, Quan Y, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 1999;4:87-94.
40. Van Leeuwen R, Katlama C, Murphy R, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 2003;17:987-99.
41. López S, Miró O, Martínez E, et al. Mitochondrial effects of antiretroviral therapies in asymptomatic patients. Antivir Ther 2004;9:47-55.
42. Kearney B, Flaherty J, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004; 43:595-612.
43. Pecora P, Kirian M. Effect of TDF on ddl absorption in patients with HIV. Ann Pharmacother 2003;37:1325-8.
44. Ray A, Olson L, Fridland A. Role of Purina nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob Agents Chemother 2004;48:1089-95.
45. Martínez E, Milinkovic A, De Lazzarin E, et al. Pancreatic toxic effects associated with coadministration of didanosine and tenofovir in HIV-infected adults. Lancet 2004;364:65-7.
46. Palacios R, Santos J, González M, et al. Reduction in body weight and CD4 lymphocyte count with simplification regimens including TDF and ddl. A scheme to avoid? 7th Int Congress on Drug Therapy in HIV Infection; 2004; Glasgow [abstract P19].
47. García-Benayas T, Barrios A, Sánchez-Conde M, et al. Higher risk of hyperglycemia in patients under didanosine and tenofovir-containing regimens. 12th CROI. In press.
48. Robbins B, Wilcox C, Fidland A, et al. Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells. Pharmacotherapy 2003;23:695-701.
49. Negredo E, Moltó J, Viciana P, et al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS 2004;18:459-63.
50. Barrios A, Negredo E, Rendón A, et al. Paradoxical CD4+ T-cell decline in patients with complete virus suppression under TDF plus ddl combinations. 44th ICAAC; 2004; Washington (DC) [abstract H-1132].
51. Arpaia E, Benvebniste P, DiCristofano A, et al. Mitochondrial basis for immune deficiency: evidence from purine nucleoside phosphorylase-deficient mice. J Exp Med 2000;191:2197-207.
52. Markert M. Purine nucleoside deficiency. Imunodef Rev 1991;3:45-81.
53. Jemsek J, Hutcherson P, Harper E. Poor virological responses and early emergence of resistance in treatment-naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine and tenofovir DF. 11th CROI; 2003; San Francisco (CA) [abstract 51].
54. 3 receiving ddl/TDF/EFV: 12 week results from a randomized comparative trial. 7th Int Congress on Drug Therapy in HIV Infection; 2004; Glasgow [abstract PL2.5].
55. Pérez M, Terrón J, Antela A, et al. Virological outcome of TDF plus ABC-based regimens in previously HIV suppressed patients (24 wk preliminary results from RECOVER study). 7th Intl Congress on Drug Therapy in HIV Infection; 2004; Glasgow [abstract P308].
56. Gallant J, Rodríguez A, Weinberg W, et al. Early non-response to TDF + ABC and 3TC in a randomized trial compared to EFV + ABC and 3TC: ESS30009 unplanned interim analysis. 43rd ICAAC; 2003; Chicago (IL) [abstract H-1722a].
57. Landman R, Peytavin G, Descamps D, et al. Low genetic barrier to resistance is a possible cause of early virologic failures in once daily regimens of abacavir, lamivudine and tenofovir: the Tonus study. 11th CROI; 2004; San Francisco (CA) [abstract 533].
58. Hoogewerf M, Regez R, Schouten W, et al. Change to abacavir/lamivudine/tenofovir combination treatment in patients with HIV-1 who had complete virological suppression. Lancet 2003;362:1979-80.
59. Kearney B, Isaacson E, Sayre J, et al. The pharmacokinetics of abacavir, a purine nucleoside analogue, are not affected by tenofovir. 43rd ICAAC; 2003; Chicago (IL) [abstract A-1615].
60. Hawkins T, Veikley W, St Claire R, et al. Intracellular pharmacokinetics of tenofovir-DP and carbovir-TP in patients receiving triple nucleoside regimens. 5th Intl Workshop on Clinical Pharmacology on HIV Therapy; 2004; Rome [abstract 6].